2225 — Jinhai Medical Technology Income Statement
0.000.00%
- HK$6.40bn
- HK$6.45bn
- SG$50.24m
Annual income statement for Jinhai Medical Technology, fiscal year end - December 31st, SGD millions except per share, conversion factor applied.
2020 December 31st | R2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 22.5 | 21.9 | 22.3 | 45.6 | 50.2 |
| Cost of Revenue | |||||
| Gross Profit | 8.85 | 7.73 | 10.1 | 12 | 11.5 |
| Selling / General / Administrative Expenses | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 20.7 | 21.8 | 21.4 | 48.6 | 67.7 |
| Operating Profit | 1.74 | 0.07 | 0.869 | -3 | -17.5 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | 1.43 | -0.062 | 0.784 | -3.22 | -18.2 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 1.26 | -0.498 | 0.116 | -4.11 | -18.3 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | 1.26 | -0.246 | 0.468 | -3.14 | -18 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 1.26 | -0.246 | 0.468 | -3.14 | -18 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0 | -0 | 0 | -0.001 | -0.003 |